<DOC>
	<DOCNO>NCT01999335</DOCNO>
	<brief_summary>The purpose Phase 1 study determine maximum tolerate dose assess safety , tolerability activity oprozomib combination pomalidomide dexamethasone subject primary refractory relapse refractory multiple myeloma . The purpose Phase 3 study compare key outcome measure subject primary refractory relapse refractory multiple myeloma randomize either oprozomib placebo combination pomalidomide dexamethasone .</brief_summary>
	<brief_title>A Study Oprozomib , Pomalidomide , Dexamethasone Subjects With Primary Refractory Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key 1 . Multiple myeloma primary refractory relapse refractory least 2 line standard multiple myeloma include : . &gt; 2 consecutive cycle bortezomib lenalidomide thalidomide ( alone combination ) . Patients receive bortezomib last therapy refractory develop bortezomib intolerance , define development Grade 2 peripheral neuropathy pain &gt; Grade 3 peripheral neuropathy ≥ 2 consecutive cycle , eligible b . Adequate alkylator therapy define : i. Highdose melphalan alkylating agent condition autologous allogeneic stem cell transplant ( SCT ) , ii . ≥ 6 cycle induction therapy , iii . PD ≥ 2 cycle 2 . Disease progression within 60 day completion last therapy 3 . Measurable disease indicate 1 following : 1 . Serum Mprotein ≥ 500 mg/dL 2 . Urine Mprotein ≥ 200 mg/24 h 3 . For patient without measurable serum urine M protein , serum free light chain ( SFLC ) : Involved free light chain ( FLC ) concentration ≥ 10 mg/dL provide SFLC ratio abnormal 4 . Males females ≥ 18 year old 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Key 1 . Systemic chemotherapy approve investigational anticancer therapeutic , include steroid therapy intend treat underlie malignancy , within 3 week first dose 6 week antibody therapy 2 . Dexamethasone cumulative dos great 160 mg equivalent within 14 day prior first dose study treatment allow . Use topical inhale steroid acceptable . 3 . Radiation therapy within 3 week first dose . Radioimmunotherapy within 8 week first dose . 4 . Autologous SCT within 8 week allogeneic SCT within 16 week prior initiation study treatment . Patients prior allogeneic SCT evidence moderatetosevere graftversushost disease ( define Filipovich 2005 ) . 5 . Known hypersensitivity immunomodulatory drug ( IMiDs ) , include Grade 4 rash 6 . Prior treatment duration pomalidomide 7 . Known hypersensitivity intolerance dexamethasone 8 . Prior exposure oprozomib 9 . Congestive heart failure ( New York Heart Association Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within 6 month first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>